The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.
Imaging assessments performed within 14 days of start of treatment
Age: 6months-30years
Measurable or evaluable disease on at least 2 dimensions on MRI at the time of treatment enrollment
Karnofsky/Lansky≥60
Pregnant or lactating women
Severe,uncontrolledactiveinfections
HIV or active HCV and/or HBV infection
Rapidly progressive disease with life expectancy < 6 weeks